Workflow
Wall Street Analysts Predict a 44.79% Upside in Arcutis Biotherapeutics (ARQT): Here's What You Should Know

Core Viewpoint - Arcutis Biotherapeutics, Inc. (ARQT) shows potential for significant upside, with a mean price target of $22.63 indicating a 44.8% increase from the current price of $15.63 [1] Price Targets - The average price target consists of eight estimates ranging from a low of $18.00 to a high of $29.00, with a standard deviation of $3.25, suggesting variability in analyst predictions [2] - The lowest estimate indicates a 15.2% increase, while the highest suggests an 85.5% upside [2] Analyst Sentiment - Analysts are optimistic about ARQT's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 21.2%, with three estimates moving higher and no negative revisions [12] Zacks Rank - ARQT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are a common metric, they should be approached with skepticism as they may not accurately predict stock price movements [3][10] - Analysts often set optimistic price targets influenced by business relationships, which can lead to inflated estimates [8]